Israel’s COVID vaccine kicks off Phase IIb trial in Georgia
NRx chairman: ‘We believe the BriLife vaccine may have better ability to deal with variants’ than others already on the market.
Hadassah-University Medical Center's Prof. Yossi Karko (left) and Hannah Drori, chief of the hospital’s clinical research center, administer Brilife vaccine to a volunteer
